
Chicago museum's fossil yields insights on famed early bird Archaeopteryx
May 14 (Reuters) - A new analysis of a pigeon-sized Archaeopteryx fossil in the collection of the Field Museum in Chicago is revealing an array of previously unknown features of the earliest-known bird, providing insight into its feathers, hands, feet and head.
The specimen, unearthed in southern Germany, is one of the most complete and best preserved of the 14 known fossils of Archaeopteryx identified since 1861. The discovery of the first Archaeopteryx fossil, with its blend of reptile-like and bird-like features, caused a sensation, lending support to British naturalist Charles Darwin's ideas about evolution and showing that birds had descended from dinosaurs.
The new study, examining the Chicago fossil using UV light to make out soft tissues and CT scans to discern minute details still embedded in the rock, shows that 164 years later there is more to learn about this celebrated creature that took flight 150 million years ago during the Jurassic Period.
The researchers identified anatomical traits indicating that while Archaeopteryx was capable of flight, it probably spent a lot of time on the ground and may have been able to climb trees.
The scientists identified for the first time in an Archaeopteryx fossil the presence of specialized feathers called tertials on both wings. These innermost flight feathers of the wing are attached to the elongated humerus bone in the upper arm. Birds evolved from small feathered dinosaurs, which lacked tertials. The discovery of them in Archaeopteryx, according to the researchers, suggests that tertials, present in many birds today, evolved specifically for flight.
Feathered dinosaurs lacking tertials would have had a gap between the feathered surface of their upper arms and the body.
"To generate lift, the aerodynamic surface must be continuous with the body. So in order for flight using feathered wings to evolve, dinosaurs had to fill this gap - as we see in Archaeopteryx," said Field Museum paleontologist Jingmai O'Connor, lead author of the study published on Wednesday in the journal Nature, opens new tab.
"Although we have studied Archaeopteryx for over 160 years, so much basic information is still controversial. Is it a bird? Could it fly? The presence of tertials supports the interpretation that the answer to both these questions is 'yes,'" O'Connor added.
The delicate specimen, preserved in three dimensions rather than squashed flat like many fossils, was painstakingly prepared to protect soft tissue remains, which glowed under ultraviolet light.
Birds are the only members of the dinosaur lineage to have survived a mass extinction 66 million years ago, caused by an asteroid striking Earth. Archaeopteryx boasted reptilian traits like teeth, a long and bony tail, and claws on its hands, alongside bird-like traits like wings formed by large, asymmetrical feathers.
The soft tissue of its toe pads appears to have been adapted for spending a lot of its life on the ground, consistent with the limited flight capabilities that Archaeopteryx is believed to have possessed.
"That's not to say it couldn't perch. It could do so still pretty well. But the point being that near the beginning of powered flight, Archaeopteryx was still spending most of its time on the ground," said study co-author Alex Clark, a doctoral student in evolutionary biology at the University of Chicago and the Field Museum.
The soft tissue on the hand suggests that the first and third fingers were mobile and could be used for climbing.
An examination of Archaeopteryx's palate - roof of the mouth - confirmed that its skull was immobile, unlike many living birds. But there was skeletal evidence of the first stages in the evolution of a trait that lets the beak move independently from the braincase, as seen in modern birds.
The fossil possesses the only complete Archaeopteryx vertebral column, including two tiny vertebrae at the tip of the tail showing it had 24 vertebrae, one more than previously thought.
The museum last year announced the acquisition of the fossil, which it said had been in the hands of a series of private collectors since being unearthed sometime before 1990.
"This specimen is arguably the best Archaeopteryx ever found and we're learning a ton of new things from it," O'Connor said.
"I consider Archaeopteryx to be the most important fossil species of all time. It is, after all, the icon of evolution, and evolution is the unifying concept of the biological sciences. Not only is Archaeopteryx the oldest-known fossil bird, with birds today being the most successful lineage of land vertebrates, it is the species that demonstrates that birds are living dinosaurs," O'Connor said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
18 hours ago
- Reuters
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
June 6 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) Adding Roche's (ROG.S), opens new tab immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting. Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon cancer patients have dMMR tumors, which do not respond well to chemotherapy. "The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," study leader Dr. Frank Sinicrope of the Mayo Clinic in Rochester, Minnesota said in a statement. The data, opens new tab were presented at the ASCO meeting that concluded earlier this week. The trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. Half of the study participants received chemotherapy along with Tecentriq, which activates the immune system to attack and kill cancer cells, for six months, followed by the immunotherapy alone for another six months. The other half of the patients received chemotherapy for 12 months. The benefit of Tecentriq was seen even in the oldest patients and those at particularly high-risk. "It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival," Sinicrope said. As patients recover after a minimally invasive heart procedure, they might be better off continuing to take a certain type of blood-thinning drug to help prevent a heart attack or stroke, instead of continuing with the traditional aspirin, a new study suggests. Early after percutaneous coronary intervention (PCI) - a procedure to prop open blocked arteries either after a heart attack, or to prevent one - patients often receive dual anti-clotting therapy with both a P2Y12 inhibitor such as clopidogrel, the generic version of Plavix, or AstraZeneca's (AZN.L), opens new tab Brilinta (ticagrelor), and aspirin. After several months, patients are usually switched from dual therapy to lifelong daily aspirin use. But pooled data looking at patients who took part in five earlier clinical trials found that continuing to prescribe the P2Y12 inhibitors and stopping the aspirin was associated with lower rates of death, heart attack and stroke compared with continuing the aspirin, with no increased risk of major bleeding, researchers reported in The BMJ, opens new tab. Overall, the trials involved 16,117 patients who received either a P2Y12 inhibitor or aspirin after completing dual therapy following PCI. After an average follow-up period of around 4 years, P2Y12 inhibitor therapy was associated with a 23% lower risk of a composite of heart-related death, heart attack, or stroke, compared with aspirin, with no significant difference in major bleeding. That translates into one prevented cardiovascular death, heart attack, or stroke for every 46 patients taking a P2Y12 inhibitor instead of aspirin after dual therapy. Overall, the findings suggest that P2Y12 inhibitor drugs should be preferred over aspirin 'due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term,' according to an editorial published with the study. But the editorial said that since patients are advised to continue the post-PCI therapy for life, large trials directly comparing the different strategies with longer follow up are needed. Some diabetes and weight-loss drugs from the class known as GLP-1 agonists were linked with a small but elevated risk for an age-related eye disease in patients with diabetes, according to a study published on Thursday in JAMA Ophthalmology, opens new tab. In 139,000 patients with diabetes, including 46,334 who had been using the GLP-1 drugs semaglutide or lixisenatide, researchers identified 181 new cases of neovascular age-related macular degeneration, also known as wet AMD. Wet AMD is a degenerative eye disease marked by the abnormal growth of blood vessels under the retina that leak fluid or blood and can lead to blindness. The risk of developing AMD during up to three years of follow-up was low, at 0.2% in GLP-1 users versus 0.1% in non-users. Still, the researchers point out, after accounting for patients' individual risk factors, the odds of AMD were doubled with at least six months of GLP-1 use and tripled in patients with the longest duration of use. Semaglutide is the active ingredient in the widely used Novo Nordisk ( opens new tab drugs Ozempic and Wegovy, while lixisenatide is the main ingredient in Sanofi's ( opens new tab discontinued Adlyxin. GLP-1 drugs have also been associated with higher risks for an eye condition known as nonarteritic anterior ischemic optic neuropathy, or NAION. Researchers did not have information about the dose, route of administration, or frequency of administration of the medications used in the study. Even with that information, the study could not have proved cause and effect. At least one earlier study with longer follow up reported that GLP-1 use was linked with a lower, rather than higher, risk for AMD. 'Our findings are not directly contradictory' with that earlier report, said study leader Dr. Reut Shor of the University of Toronto. 'Factors such as timing and duration of exposure, disease stage, and patient characteristics may all influence outcomes," Shor said. "Our results add another layer to the emerging understanding of this complex relationship and emphasize the need for further research to clarify these trends.' (To receive the full newsletter in your inbox for free sign up here)


Daily Mirror
19 hours ago
- Daily Mirror
'Strawberry Moon' to rise in rare sky event not repeating until 2043
The first full Moon of meteorological summer, known as the 'Strawberry Moon', will light up the skies for stargazers on June 11 - the Moon will sit low in the southern sky Stargazers in the UK are gearing up for a cosmic display as the 'Strawberry Moon' is set to rise next week, but something's different this time around. June's full Moon is an event that casts a glow on our celestial neighbour when sunlight completely illuminates the side of the Moon facing Earth – an occurrence that takes place every 29.5 days, marking a full lunar cycle. The approach of summer heralds the first full Moon of the season, affectionately termed the 'Strawberry Moon', scheduled to grace the night sky on June 11. However, due to a recent occurrence known as a "major lunar standstill", this year's Strawberry Moon will find itself in an atypical position in the British skies. Observers can expect to see the full Strawberry Moon hanging unusually low in the southern sky - the lowest it gets throughout its 18.6-year orbital journey. It's been a long time since the full Moon appeared so low, with the previous occurrence dating back over 18 years to 2006, and it won't repeat until 2043. But what exactly makes the Strawberry Moon standout, and does it actually look different? The Moon dances around Earth in a tilted orbit, which spans almost 20 years, leading to interesting phenomena such as major and minor lunar standstills, during which the Moon reaches extreme points on the horizon, making it appear peculiarly low or high in the sky. Stargazers are in for a treat as the Strawberry Moon is set to rise just 10 days before the summer solstice on June 21, promising a celestial spectacle, reports the Manchester Evening News. NASA has revealed that moons generally appear lower in the sky around the summer solstice, explaining: "On the summer solstice the sun appears highest in the sky for the year. Full moons are opposite the sun, so a full moon near the summer solstice will be low in the sky." Not only will the Moon be hanging low in the night sky, but it's also expected to look larger than usual, with BBC Sky at Night Magazine confirming this illusion. The reason behind the Moon's enlarged appearance is its proximity to the horizon, which tends to make it seem more substantial than it actually is. Best time to see 'Strawberry Moon' in UK For those keen to catch a glimpse of the 'Strawberry Moon' in the UK, mark your calendars for 8.44am BST when the Moon will reach its full phase. Although it will be daylight by then, with sunrise at approximately 4.45am on June 11, the prime viewing time will be at dusk on Tuesday, June 10, when the Moon will dominate the night sky, appearing full all through the night. Why it's called the 'Strawberry Moon'? Each month's full Moon has its own unique moniker; January's is known as the 'Wolf Moon', while February's is dubbed the ' Snow Moon'. Despite not taking on a berry-like hue, the 'Strawberry Moon' owes its name to the season when wild strawberries begin to ripen, as noted by the Farmers' Almanac. Other traditional names for this June spectacle include Rose Moon, Hot Moon, and Mead Moon. Below is the full Moon schedule for 2025, as well as the name given to each one: Monday, January 13 – Wolf Moon Wednesday, February 12 – Snow Moon Friday, March 14 – Worm Moon Saturday, April 12 – Pink Moon (Micromoon) Monday, May 12 – Flower Moon (Micromoon) Wednesday, June 11 – Strawberry Moon Thursday, July 10 – Buck Moon Saturday, August 9 – Sturgeon Moon Monday, October 6 – Hunter's Moon (Supermoon) Wednesday, November 5 – Beaver Moon (Supermoon) Thursday, December 4 – Cold Moon (Supermoon)


The Independent
19 hours ago
- The Independent
Chimpanzees can ‘catch' yawns even from robots
Chimpanzees can 'catch' yawns from an android robot imitating human facial expressions, according to a new study that raises more questions about the evolutionary origins of the behaviour. Yawning is known to be associated with attention changes, regulating body temperature, and as a transition between rest and arousal. Contagious yawning is a strange behaviour in which an animal yawns after seeing another individual exhibit the same behaviour. This contagious aspect of the behaviour has been linked to some elements of social interaction, like empathy and imitation. Until now, contagious yawning has been observed in mammals and some fish, but its evolutionary origins are still unknown. It emerges gradually in humans, chimpanzees, and dogs, becoming prominent at around four years in humans, five years in chimpanzees, and at about seven months in dogs, scientists say. The new study, published on Thursday in the journal Nature, found that chimpanzees will both yawn and lie down in response to yawns made by an android robot. The findings suggest that observing another individual yawn may act as a cue in chimps to rest rather than triggering an automatic response. In the study, scientists used an android head that could simulate facial expressions to test the responses of 14 adult chimps aged between 10 and 33 years. The android head contained 33 rotational motors which functioned as muscles to generate its facial expressions, including yawns, with each expression lasting 10 seconds. Chimps in the study were each exposed to four 15-minute sessions of the android demonstrating yawning, gaping, and neutral facial expressions. Scientists recorded these sessions on camera, and each chimpanzee was scored for their responsiveness, along with the amount of time they spent lying down. Eight of the 14 chimpanzees were found to yawn in response to the android's 'yawn' expression. 'The results showed that adult chimpanzees exhibited across-agent yawn contagion, with a graded response: the highest contagion occurred when the android displayed a fully wide-open mouth, a reduced response when the mouth was partially opened, and no contagion when the android's mouth was closed,' they wrote. Eight chimps also lay down in response, and some gathered bedding before lying down. 'Chimpanzees engaged in behaviours associated with drowsiness, such as gathering bedding materials, constructing nests, and lying down, while observing the android yawning,' scientists wrote. These findings seem to show contagious yawning due to an inanimate model for the first time, according to researchers. The results shed further light on primates' susceptibility to contagiously induced behaviours, scientists say, adding, however, that the exact biological mechanisms surrounding it remain unclear. They hope future research can reveal whether other actions performed by robots are contagious to animals.